ClinicalTrials.gg
Active, not recruitingNCT07210463PLATINUM EUUpdated Nov 6, 2026

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)

A Phase 3 interventional study of NT 201 and NT 201 Placebo in Neuromuscular Agents, Peripheral Nervous System Agents and Physiological Effects of Drugs, sponsored by Merz Aesthetics GmbH. Active, not recruiting at 26 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Merz Aesthetics GmbH (part of Merz Pharma) · Phase 3, Interventional, and Treatment

Updated Nov 6, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence. The study will be conducted in two periods: Main Period (MP) and Open label Extension Period (OLEX).

02

Conditions studied

  • Neuromuscular Agents
  • Peripheral Nervous System Agents
  • Physiological Effects of Drugs
  • Acetylcholine Release Inhibitors
  • Membrane Transport Modulators
  • Molecular Mechanisms of Pharmacological Action
  • Cholinergic Agents
  • Neurotransmitter Agents
  • incobotulinumtoxinA
  • Botulinum Toxins, Type A

Keywords

  • Platysma prominence
03

In context

Lead sponsor

Merz Aesthetics GmbH is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presence of four (medial and lateral, left and right) platysmal bands assessed at screening and baseline.
  • A score of Grade 3 ('moderate') or Grade 4 ('severe') on the MAPSD at maximum contraction by the investigator AND participant.

Exclusion criteria

Exclusion Criteria:

  • or a history of allergic reaction to botulinum toxin of any serotype or any of their formulation ingredients.
  • Any medical condition that may put the participant at increased risk with exposure to botulinum toxin of any serotype, or any disorders that might interfere with neuromuscular function.
  • Any serious disease or disorder that could interfere with the safe completion of treatment or with study outcome assessments, or compromise participant safety.
  • Botulinum toxin treatment in the face (below the lower orbital rim), jawline, or neck within the last seven months.
  • History of lower face surgery, neck or chest surgery, and aesthetic procedures in the past 12 months and/or orthodontic procedures in the past 6 months.
  • Planned surgery or aesthetic procedures to the lower face, neck, or chest during the study period.
  • Anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study products).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    Main Period: NT 201

    Participants will receive NT 201 IM injection, once on Day 1 of the MP.

    Drug: NT 201

  • Placebo comparator
    Main Period: NT 201 Matching Placebo

    Participants will receive NT 201 matching placebo IM injection, once on Day 1 of the MP.

    Drug: NT 201 Placebo

  • Experimental
    OLEX Period: NT 201

    Participants will receive a reinjection of NT 201 IM injection, once on Day 1 of OLEX period.

    Drug: NT 201

Interventions

  • DrugNT 201

    Clostridium Botulinum neurotoxin A (150 kiloDalton \[kD\], free of complexing proteins), powder for solution for injection.

    Also known as: IncobotulinumtoxinA, Xeomin/Bocouture, Xeomin Cosmetic, Xeomeen

  • DrugNT 201 Placebo

    NT 201 matching-placebo.

06

What researchers measure

Primary outcomes

  1. Composite Achievement of Grade 1 or Grade 2 and at Least a 2-Grade Improvement From Baseline Based on Both the Investigator's Assessment and Participant's Self-Assessment Using the Merz Aesthetics Platysma Scale Dynamic (MAPSD) At Week 2 of MP

    MAPSD is a validated five-point scale that will be used to grade the platysma prominence. Scores range from Grade 1 (none to minimal) to Grade 5 (very severe). A lower score indicates improvement.

    Time frame: At Week 2 of MP

Secondary outcomes

  1. Achievement of Grade 1 (None to Minimal) or Grade 2 (Mild) and at Least a 2-Grade Improvement From Baseline Based on the Investigator's Assessment Using MAPSD at Week 2 of MP

    MAPSD is a validated five-point scale that will be used to grade the platysma prominence. Scores range from Grade 1 (none to minimal) to Grade 5 (very severe). A lower score indicates improvement.

    Time frame: At Week 2 of MP

  2. Achievement of Grade 1 (None to Minimal) or Grade 2 (Mild) and at Least a 2-Grade Improvement From Baseline Based on the Participant's Self-Assessment Using MAPSD at Week 2 of MP

    MAPSD is a validated five-point scale that will be used to grade the platysma prominence. Scores range from Grade 1 (none to minimal) to Grade 5 (very severe). A lower score indicates improvement.

    Time frame: At Week 2 of MP

  3. Achievement of at Least a +1 (Somewhat Satisfied) Score Using the Participant's Satisfaction Questionnaire at Week 2 of MP

    Participants satisfaction questionnaire responses will be rated on a scale ranging from +3 (very satisfied) to -3 (very dissatisfied). A higher score indicates satisfaction.

    Time frame: At Week 2 of MP

  4. Achievement of Grade 1 (None to Minimal) or Grade 2 (Mild) and at Least a 2-Grade Improvement From Baseline Based on Both the Investigator's Assessment and Participant's Self-Assessment Using MAPSD at Week 1 and Week 4 up to Week 17 of MP

    MAPSD is a validated five-point scale that will be used to grade the platysma prominence. Scores range from Grade 1 (none to minimal) to Grade 5 (very severe). A lower score indicates improvement.

    Time frame: At Week 1 and Week 4 up to Week 17 of MP

  5. Achievement of Grade 1 (None to Minimal) or Grade 2 (Mild) and at Least a 2-Grade Improvement From Baseline Based on the Investigator's Assessment Using MAPSD at Week 1 and Week 4 up to Week 17 of MP

    MAPSD is a validated five-point scale that will be used to grade the platysma prominence. Scores range from Grade 1 (none to minimal) to Grade 5 (very severe). A lower score indicates improvement.

    Time frame: At Week 1 and Week 4 up to Week 17 of MP

  6. Achievement of Grade 1 (None to Minimal) or Grade 2 (Mild) and at Least a 2-Grade Improvement From Baseline Based on Participant's Self-Assessment Using MAPSD at Week 1 and Week 4 up to Week 17 of MP

    MAPSD is a validated five-point scale that will be used to grade the platysma prominence. Scores range from Grade 1 (none to minimal) to Grade 5 (very severe). A lower score indicates improvement.

    Time frame: At Week 1 and Week 4 up to Week 17 of MP

  7. Achievement of at Least a +1 (Improved) Score on the Global Aesthetic Improvement Scale (GAIS)-Platysmal Bands at maximum contraction Based on the Investigator's Assessment at Week 2 of MP

    GAIS is a balanced seven-point Likert scale (range -3 \[very much worse\] to +3 \[very much improved\]) commonly used in aesthetic medicine to rate post-treatment improvement in appearance. A higher score indicates improvement.

    Time frame: At Week 2 of MP

  8. Achievement of at Least a +1 (Improved) Score on the GAIS-Platysmal Bands at maximum contraction Based on the Participant's Self-Assessment at Week 2 of MP

    GAIS is a balanced seven-point Likert scale (range -3 \[very much worse\] to +3 \[very much improved\]) commonly used in aesthetic medicine to rate post-treatment improvement in appearance. A higher score indicates improvement.

    Time frame: At Week 2 of MP

  9. Achievement of at Least a +1 (Improved) Score on the GAIS-Platysmal Bands at Rest Based on the Investigator's Assessment at Week 2 of MP

    GAIS is a balanced seven-point Likert scale (range -3 \[very much worse\] to +3 \[very much improved\]) commonly used in aesthetic medicine to rate post-treatment improvement in appearance. A higher score indicates improvement.

    Time frame: At Week 2 of MP

  10. Achievement of at Least a +1 (Improved) Score on the GAIS-Platysmal Bands at Rest Based on the Participant's Self-Assessment at Week 2 of MP

    GAIS is a balanced seven-point Likert scale (range -3 \[very much worse\] to +3 \[very much improved\]) commonly used in aesthetic medicine to rate post-treatment improvement in appearance. A higher score indicates improvement.

    Time frame: At Week 2 of MP

  11. Achievement of at Least a +1 (Improved) Score Using the GAIS-Lower Face Contour According to the Investigator's Assessment at Week 2 of MP

    GAIS is a balanced seven-point Likert scale (range -3 \[very much worse\] to +3 \[very much improved\]) commonly used in aesthetic medicine to rate post-treatment improvement in appearance. A higher score indicates improvement.

    Time frame: At Week 2 of MP

  12. Achievement of at Least a +1 (Improved) Score Using the GAIS-Lower Face Contour According to the Participant's Self-Assessment at Week 2 of MP

    GAIS is a balanced seven-point Likert scale (range -3 \[very much worse\] to +3 \[very much improved\]) commonly used in aesthetic medicine to rate post-treatment improvement in appearance. A higher score indicates improvement.

    Time frame: At Week 2 of MP

07

Study locations

26 sites
  • Merz Investigative Site
    Lyon, 69006, France
  • Merz Investigative Site
    Munich, Bavaria 80539, Germany
  • Merz Investigative Site
    Blankenfelde-Mahlow, Brandenburg 15831, Germany
  • Merz Investigative Site
    Potsdam, Brandenburg 14467, Germany
  • Merz Investigative Site
    Friedrichsdorf, Hesse 61381, Germany
  • Merz Investigative Site
    Kassel, Hesse 34117, Germany
  • Merz Investigative Site
    Bochum, North Rhine-Westphalia 44793, Germany
  • Merz Investigative Site
    Düsseldorf, North Rhine-Westphalia 40212, Germany
  • Merz Investigative Site
    Drensteinfurt, 48317, Germany
  • Merz Investigative Site
    Hamburg, 20146, Germany
  • Merz Investigative Site
    Hamburg, 29354, Germany
  • Merz Investigative Site
    Wuppertal, 42287, Germany
  • Merz Investigative Site
    Krakow, Lesser Poland Voivodeship 30-002, Poland
  • Merz Investigative Site
    Oświęcim, Lesser Poland Voivodeship 32-600, Poland
  • Merz Investigative Site
    Lublin, Lublin Voivodeship 20-607, Poland
  • Merz Investigative Site
    Warsaw, Masovian Voivodeship 00-716, Poland
  • Merz Investigative Site
    Warsaw, Masovian Voivodeship 01-142, Poland
  • Merz Investigative Site
    Warsaw, Masovian Voivodeship 02-482, Poland
  • Merz Investigative Site
    Warsaw, Masovian Voivodeship 02-953, Poland
  • Merz Investigative Site
    Bialystok, Podlaskie Voivodeship 15-453, Poland
  • Merz Investigative Site
    Gdynia, Pomeranian Voivodeship 81-537, Poland
  • Merz Investigative Site
    Warsaw, 02-962, Poland
  • Merz Investigative Site
    Lodz, Łódź Voivodeship 90-436, Poland
  • Merz Investigative Site
    Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship 27-400, Poland
  • Merz Investigative Site
    Pamplona, Navarre 31008, Spain
  • Merz Investigative Site
    Valencia, 46010, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2025 to primary completion in Aug 2026, 10 months.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Aug 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2025
First posted
Oct 7, 2025
StartActual
Oct 1, 2025
Primary completionActual
Aug 5, 2026was Oct 2026
CompletionEst.
Aug 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Aug 5, 2026 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Oct 2026→Aug 5, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07210463
Responsible party
Sponsor
First posted
Oct 7, 2025
Start date
Oct 1, 2025
Primary completion
Aug 5, 2026
Completion
Aug 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Merz Medical Expert
study director · Merz Aesthetics GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: incobotulinumtoxinA

Start the discussion